Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. - Université de Bretagne Occidentale Access content directly
Journal Articles Blood Year : 2015

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Bruno Cassinat

Abstract

Myeloproliferative neoplasms are clonal disorders characterized by the presence of several gene mutations associated with particular hematologic parameters, clinical evolution, and prognosis. Few therapeutic options are available, among which interferon α (IFNα) presents interesting properties like the ability to induce hematologic responses (HRs) and molecular responses (MRs) in patients with JAK2 mutation. We report on the response to IFNα therapy in a cohort of 31 essential thrombocythemia (ET) patients with CALR mutations (mean follow-up of 11.8 years). HR was achieved in all patients. Median CALR mutant allelic burden (%CALR) significantly decreased from 41% at baseline to 26% after treatment, and 2 patients even achieved complete MR. In contrast, %CALR was not significantly modified in ET patients treated with hydroxyurea or aspirin only. Next-generation sequencing identified additional mutations in 6 patients (affecting TET2, ASXL1, IDH2, and TP53 genes). The presence of additional mutations was associated with poorer MR on CALR mutant clones, with only minor or no MRs in this subset of patients. Analysis of the evolution of the different variant allele frequencies showed that the mutated clones had a differential sensitivity to IFNα in a given patient, but no new mutation emerged during treatment. In all, this study shows that IFNα induces high rates of HRs and MRs in CALR-mutated ET, and that the presence of additional nondriver mutations may influence the MR to therapy.

Dates and versions

hal-01276534 , version 1 (19-02-2016)

Identifiers

Cite

Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Christine Dosquet, Stephane Giraudier, et al.. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.. Blood, 2015, 126 (24), pp.2585-91. ⟨10.1182/blood-2015-07-659060⟩. ⟨hal-01276534⟩
207 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More